Search Results | DrugBank Online

Did you mean urea c 10 and catus acid?

Displaying drugs 14826 - 14850 of 15902 in total

QS-21

QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being...

Investigational

Matched Description: … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies …

IDD-3

IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.

Investigational

SGN-30

SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...

Investigational

Matched Description: … SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is ... SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February ... 30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and …

HSV-2 theracine

HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

Investigational

Q-Derp1

Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.

Investigational

BI-K0376

BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

Investigational

Matched Description: … It is under investigation by Pfizer and has gone through phase I of the clinical trails. …

TRX1

TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

Investigational

HGS-TR2J

HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

Investigational

Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. …

FAV-201

FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.

Investigational

Gavilimomab

Investigational

Liquidambar styraciflua resin

Experimental

Insulin argine

Experimental

Placulumab

Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis.

Investigational

Glucagon-like peptide II

Glucagon-like peptide II is under investigation for the basic science of Short Bowel Syndrome.

Investigational

Denenicokin

Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).

Investigational